EEF1A1 and hemophilia A: These first proof-of-concept experiments demonstrate that the insertion of the EF1α promoter with the FVIII gene in the human FVIII locus is a suitable strategy for the restoration of FVIII expression, and provides a valuable and universal tool for future ex vivo cell therapy for patients with hemophilia A.